LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Recursion Pharmaceuticals Inc

Cerrado

SectorSanidad

5.01 -7.56

Resumen

Variación precio

24h

Actual

Mínimo

4.98

Máximo

5.47

Métricas clave

By Trading Economics

Ingresos

-24M

-202M

Ventas

10M

15M

BPA

-0.5

Margen de beneficios

-1,373.259

Empleados

800

EBITDA

-26M

-191M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

+21.12% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-276M

2B

Apertura anterior

12.57

Cierre anterior

5.01

Noticias sobre sentimiento de mercado

By Acuity

60%

40%

335 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Recursion Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

27 jun 2025, 20:51 UTC

Ganancias

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 jun 2025, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 jun 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

27 jun 2025, 20:48 UTC

Charlas de Mercado

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 jun 2025, 20:46 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

27 jun 2025, 20:46 UTC

Charlas de Mercado

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 jun 2025, 19:31 UTC

Charlas de Mercado

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 jun 2025, 19:19 UTC

Charlas de Mercado

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 jun 2025, 19:16 UTC

Charlas de Mercado

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 jun 2025, 18:57 UTC

Adquisiciones, fusiones, absorciones

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 jun 2025, 18:42 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 jun 2025, 18:42 UTC

Charlas de Mercado

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 jun 2025, 18:39 UTC

Charlas de Mercado
Ganancias

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 jun 2025, 18:29 UTC

Charlas de Mercado

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 jun 2025, 18:18 UTC

Charlas de Mercado

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 jun 2025, 18:16 UTC

Charlas de Mercado

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 jun 2025, 17:16 UTC

Charlas de Mercado

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 jun 2025, 17:08 UTC

Ganancias

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 jun 2025, 16:52 UTC

Adquisiciones, fusiones, absorciones

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 jun 2025, 16:22 UTC

Ganancias

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 jun 2025, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

27 jun 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 jun 2025, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

27 jun 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

27 jun 2025, 15:59 UTC

Charlas de Mercado

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 jun 2025, 15:56 UTC

Charlas de Mercado

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Comparación entre iguales

Cambio de precio

Recursion Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

21.12% repunte

Estimación a 12 Meses

Media 6.25 USD  21.12%

Máximo 8 USD

Mínimo 4 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Recursion Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

5 ratings

1

Comprar

4

Mantener

0

Vender

Puntuación técnica

By Trading Central

4.15 / 4.75Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bearish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

335 / 380 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.